Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AZTherapies, Inc.
Experts say there should be enough Alzheimer’s patients willing to enroll in Biogen/Eisai’s US FDA-required Phase IV trial and other companies’ late-stage studies even with Aduhelm broadly available.
Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Smith Therapeutics